Changes in the Rate of and Trends in Colectomy for Ulcerative Colitis During the Era of Biologics and Calcineurin Inhibitors Based on a Japanese Nationwide Cohort Study

Overview

Journal Surg Today

Specialty General Surgery

Date 2019 Jul 17

PMID 31309329

Citations 16

Authors

Motoi Uchino

Hiroki Ikeuchi

Keisuke Hata

Satoshi Okada

Soichiro Ishihara

Koji Morimoto

Rikisaburo Sahara

Kazuhiro Watanabe

Kouhei Fukushima

Kenichi Takahashi

Hideaki Kimura

Keiji Hirata

Tsunekazu Mizushima

Toshimitsu Araki

Masato Kusunoki

Riichiro Nezu

Sayumi Nakao

Michio Itabashi

Akira Hirata

Heita Ozawa

Takashi Ishida

Koji Okabayashi

Takayuki Yamamoto

Toshihiro Noake

Junya Arakaki

Yusuke Watadani

Hiroki Ohge

Ryo Futatsuki

Kazutaka Koganei

Akira Sugita

Daijiro Higashi

Kitaro Futami

Affiliations

Soon will be listed here.

Abstract

Purpose: We evaluated the recent incidence of surgery and the changing surgery trends for ulcerative colitis (UC) in Japan due to the increasing use of anti-tumor necrosis factor (TNF) agents.

Methods: A questionnaire survey was performed to assess the number of surgeries, surgical indications, surgical timing, and immunosuppressive treatments before surgery between 2007 and 2017.

Results: A total of 3801 surgical cases were reported over 11 years. The prevalence of UC surgery decreased over the period studied. The rate of prednisolone (PSL) use did not change. The prevalence of both calcineurin inhibitors (CNIs) and anti-TNF agents increased during the period studied (p < 0.01). The prevalence of urgent/emergent surgery did not change. The most distinctive change in surgical indications was the increase in cancer/dysplasia (CAC), the prevalence of which increased from 20.2% in 2007 to 34.8%.

Conclusion: The prevalence of UC surgery seems to be decreasing according to the increasing rate of anti-TNF agent and CNI administration. However, the indication of CAC significantly increased. Further research should evaluate whether or not long-term remission maintained with several agents can lead to increasing CAC.

Citing Articles

Colorectal Neoplasia in Inflammatory Bowel Disease.

Al Sulais E, AlAmeel T, Alenzi M, Shehab M, AlMutairdi A, Al-Bawardy B Cancers (Basel). 2025; 17(4).

PMID: 40002259 PMC: 11853504. DOI: 10.3390/cancers17040665.

Genetic Analysis of Biopsy Tissues from Colorectal Tumors in Patients with Ulcerative Colitis.

Yamamoto N, Urabe Y, Nakahara H, Nakamura T, Shimizu D, Konishi H Cancers (Basel). 2024; 16(19).

PMID: 39409892 PMC: 11475702. DOI: 10.3390/cancers16193271.

Long-term prognosis and clinical practice for new-onset ulcerative colitis in the era of biologics: A Japanese retrospective study.

Moroi R, Kakuta Y, Obara T, Shimoyama Y, Naito T, Shiga H JGH Open. 2023; 7(10):682-689.

PMID: 37908295 PMC: 10615172. DOI: 10.1002/jgh3.12957.

Associations between Pouchitis and Fecal Calprotectin after Restorative Proctocolectomy in Patients with Ulcerative Colitis.

Uchino M, Horio Y, Kuwahara R, Kusunoki K, Nagano K, Ikeuchi H Inflamm Intest Dis. 2023; 8(2):77-83.

PMID: 37901341 PMC: 10601934. DOI: 10.1159/000531654.

Have advances in medical therapy for ulcerative colitis impacted surgical treatment?.

Kuwahara R, Ikeuchi H, Horio Y, Minagawa T, Kusunoki K, Uchino M Ann Gastroenterol Surg. 2023; 7(2):272-278.

PMID: 36998292 PMC: 10043766. DOI: 10.1002/ags3.12626.

References

Reich K, Chang H, Rezaie A, Wang H, Goodman K, Kaplan G . The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. Aliment Pharmacol Ther. 2014; 40(6):629-38. DOI: 10.1111/apt.12873. View

Sandborn W, Rutgeerts P, Feagan B, Reinisch W, Olson A, Johanns J . Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009; 137(4):1250-60. DOI: 10.1053/j.gastro.2009.06.061. View

Kaplan G, Seow C, Ghosh S, Molodecky N, Rezaie A, Moran G . Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol. 2012; 107(12):1879-87. DOI: 10.1038/ajg.2012.333. View

Chow D, Leong R, Tsoi K, Ng S, Leung W, Wu J . Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol. 2009; 104(3):647-54. DOI: 10.1038/ajg.2008.74. View

Leijonmarck C, Persson P, Hellers G . Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut. 1990; 31(3):329-33. PMC: 1378277. DOI: 10.1136/gut.31.3.329. View

Campbell S, Travis S, Jewell D . Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol. 2005; 17(1):79-84. DOI: 10.1097/00042737-200501000-00016. View

Ekbom A, HELMICK C, Zack M, Adami H . Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990; 323(18):1228-33. DOI: 10.1056/NEJM199011013231802. View

Eaden J, Abrams K, Mayberry J . The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48(4):526-35. PMC: 1728259. DOI: 10.1136/gut.48.4.526. View

Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T . Prevalence of ulcerative colitis and Crohn's disease in Japan. J Gastroenterol. 2009; 44(7):659-65. DOI: 10.1007/s00535-009-0057-3. View

10.

Kakeji Y, Takahashi A, Udagawa H, Unno M, Endo I, Kunisaki C . Surgical outcomes in gastroenterological surgery in Japan: Report of National Clinical database 2011-2016. Ann Gastroenterol Surg. 2018; 2(1):37-54. PMC: 5881362. DOI: 10.1002/ags3.12052. View

11.

Higashi A, Watanabe Y, Ozasa K, Hayashi K, AOIKE A, Kawai K . Prevalence and mortality of ulcerative colitis and Crohn's disease in Japan. Gastroenterol Jpn. 1988; 23(5):521-6. DOI: 10.1007/BF02779483. View

12.

Komaki Y, Komaki F, Ido A, Sakuraba A . Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. J Crohns Colitis. 2015; 10(4):484-94. PMC: 4946757. DOI: 10.1093/ecco-jcc/jjv221. View

13.

Yamadera M, Ueno H, Kobayashi H, Konishi T, Ishida F, Yamaguchi T . Current status of prophylactic surgical treatment for familial adenomatous polyposis in Japan. Surg Today. 2016; 47(6):690-696. DOI: 10.1007/s00595-016-1431-4. View

14.

Narula N, Fine M, Colombel J, Marshall J, Reinisch W . Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks?. Inflamm Bowel Dis. 2015; 21(7):1683-94. DOI: 10.1097/MIB.0000000000000350. View

15.

Molodecky N, Soon I, Rabi D, Ghali W, Ferris M, Chernoff G . Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2011; 142(1):46-54.e42. DOI: 10.1053/j.gastro.2011.10.001. View

16.

Langholz E, Munkholm P, Davidsen M, Binder V . Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992; 103(5):1444-51. DOI: 10.1016/0016-5085(92)91163-x. View

17.

Eriksson C, Cao Y, Rundquist S, Zhulina Y, Henriksson I, Montgomery S . Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963-2010. Aliment Pharmacol Ther. 2017; 46(8):748-757. DOI: 10.1111/apt.14268. View

18.

Moskovitz D, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S . Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006; 4(6):760-5. DOI: 10.1016/j.cgh.2006.04.001. View

19.

Kimura H, Takahashi K, Futami K, Ikeuchi H, Tatsumi K, Watanabe K . Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan. Surg Today. 2015; 46(8):930-8. DOI: 10.1007/s00595-015-1259-3. View

20.

Moore S, McGrail K, Peterson S, Raval M, Karimuddin A, Phang P . Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada. Dis Colon Rectum. 2013; 57(1):83-90. DOI: 10.1097/DCR.0000000000000003. View